The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog

Cardiovascular Research

Volumn 37, Issue 3, 1998, Pages 656-666

  Libersan, Danielle ^a,b   Khalil, Ahmad ^a   Dagenais, Pierre ^a   Quan, Eric ^a   Delorme, Fernand ^c   Uzan, André ^d   Latour, Jean Gilles ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Rhône Poulenc Rorer   (Canada)

^d SANOFI   (France)

Author keywords

Dog; Leukocyte; Low molecular weight heparin; Myocardial infarction; Platelet; Reperfusion; Stenosis; Streptokinase

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; STREPTOKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; COLLATERAL CIRCULATION; CONTROLLED STUDY; COVARIANCE; DOG; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ADHESION;

ANALYSIS OF VARIANCE; ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; CELLS, CULTURED; DOGS; ENOXAPARIN; ERYTHROCYTES; FEMALE; HEPARIN; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEUTROPHILS; PLATELET ADHESIVENESS; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 0032029106     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00292-7     Document Type: Article

References (48)

1. [1] Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword?. J Clin Invest 1985;76:1713-1719.
2. [2] Latour, JG. Impaired postischemic reflow and myocardial reperfusion injury. In: The age of reperfusion, vol. 4. New York, NY: Cahners Med., 1992:5-11.
3. [3] Rousseau G, Hébert D, Libersan D, et al. Importance of platelets in myocardial injury after reperfusion in the presence of residual coronary stenosis in dogs. Am Heart J 1993;125:1553-1563.
4. [4] The TIMI Study Group, Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1989;320:618-627.
5. [5] Folts JD, Crowell EB Jr, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976;54:365-370.
6. [6] Becker RC, Gore JM. The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. Cardiology 1993;83:100-106.
7. [7] Black SC, Gralinski MR, Friedrichs GS, et al. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res 1995;29:629-636.
8. [8] Redini F, Tixier JM, Petitou M, et al. Inhibition of leucocyte elastase by heparin and its derivatives. Biochem J 1988;252:515-519.
9. [9] Edens, RE, Linhardt, RJ, Weiler, JM. Heparin is not just an anticoagulant anymore: six and one-half decades of studies on the ability of heparin to regulate complement activity. In: Cruse, JM, Lewis Jr, RE, editors. Complement profiles, vol. 1. Basel, Switzerland: Karger, 1993:96-120.
10. [10] Nelson RM, Cecconi O, Roberts WG, et al. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
11. [11] Silvestro L, Viano I, Macario M, et al. Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Semin Thromb Haemost 1994;20:254-258.
12. [12] Grant D, Long WF, Mackintosh G, Williamson FB. Heparins as essential antioxidants. Agents Actions 1994;41:C214-C215.
13. [13] Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thrombotic disorders. Drugs 1992;44:465-497.
14. [14] Higginson LAJ, White F, Heggtveit HA, et al. Determinants of myocardial hemorrhage after coronary reperfusion in the anesthetized dog. Circulation 1982;65:62-69.
15. [15] Blajchman, MA, Young, E, Ofosu, FA. Effects of unfractionned heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits. In: Ofosu, FA, Danishefsky, I, Hirsh, J, Editors. Heparin and related polysaccharides. Structure and activities. New York, NY: The New York Academy of Sciences, 1989;556:245-254.
16. [16] Landolfi R, De Candia E, Rocca B, et al. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis 'in vivo'. Thromb Haemost 1994;72:942-946.
17. [17] Itoh K, Nakao A, Kishimoto W, Takagi H. Heparin effects on superoxide production by neutrophils. Eur Surg Res 1995;27:184-188.
18. [18] Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993;70:625-630.
19. [19] Antman EM, McCabe CH, Marble SJ, et al. Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11A. Circulation 1996;94:I-554.
20. [20] Rousseau G, Provost P, Tran D, et al. Clentiazem given at reperfusion improves subendocardial reflow and reduces myocardial infarct size in the dog. J Pharmacol Exp Ther 1994;268:1252-1260.
21. [21] Bednar M, Smith B, Pinto A, Mullane KM. Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 1985;57:131-141.
22. [22] Handeland G. Simplified chromogenic substrate assay for low molecular weight heparin. Thromb Res 1986;42:105-108.
23. [23] Doré M, Burns AR, Hughes BJ, Entman ML, Smith CW. Chemoattractant-induced changes in surface expression and redistribution of a functional ligand for P-selectin on neutrophils. Blood 1996;87(5):2029-2037.
24. [24] Spagenberg P, Redlich H, Bergmann I, et al. The platelet glycoprotein IIb/IIIa is involved in the adhesion of activated platelets to leukocytes. Thromb Haemostas 1993;70(3):514-521.
25. 2 responses in stimulated human neutrophils. Identification of platelet factor as adenine nucleotide. Lab Invest 1988;58:37-47.
26. [26] Marcus AJ, Broekman MJ, Safier LB, et al. Formation of leukotrienes and other hydroxy acids during platelet-neutrophil interactions in vitro. Biochem Biophys Res Commun 1982;109:130-137.
27. [27] Tsuji T, Nagata K, Koike J, et al. Induction of superoxide anion production from monocytes and neutrophils by activated platelets through the P-selectin - sialyl Lewis X interaction. J Leukocyte Biol 1994;56:583-587.
28. [28] McEver RP, Moore KL, Cummings RD. Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 1995;270:11025-11028.
29. [29] Lefer AM, Weyrich AS, Buerke M. Role of selectins, a new family of adhesion molecules, in ischaemia-reperfusion injury. Cardiovasc Res 1994;28:289-294.
30. x analog attenuates neutrophil accumulation and myocardial necrosis after ischemia and reperfusion. Circulation 1994;90:2390-2401.
31. [31] Weyrich AS, Ma XL, Lefer DJ, Albertine KH, Lefer AM. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest 1993;91:2620-2629.
32. [32] Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986;261:3980-3986.
33. [33] Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Annu Rev Physiol 1990;52:561-576.
34. [34] de Lorgeril M, Rousseau G, Basmadjian A, et al. Spacial and temporal profiles of neutrophil accumulation in the reperfused ischemic myocardium. Am J Cardiovasc Pathol 1990;3:143-154.
35. [35] de Lorgeril M, Basmadjian A, Lavallée M, et al. Influence of leukopenia on collateral flow, reperfusion flow, reflow ventricular fibrillation and infarct size in dogs. Am Heart J 1989;117:523-532.
36. [36] Friedrichs GS, Kilgore KS, Manley PJ, Gralinski MR, Lucchesi BR. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res 1994;75:701-710.
37. [37] Lucchesi BR. Complement activation, neutrophils, and oxygen radicals in reperfusion injury. Stroke 1993;24(suppl. 1):I41-I47.
38. [38] Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-9060.
39. [39] Gikasis N, Khan MMH, Hiramatsu Y, et al. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation 1996;94(suppl. II):II341-II346.
40. [40] Noris P, Bertolino G, Previtali M, Ferrario M, Balduini CL. Heparin infusion facilitates ex vivo spontaneous platelet aggregation in patients with acute myocardial infarction who have undergone thrombolytic therapy. Haemostasis 1993;23:185-191.
41. [41] El Habbal MH, Smith L, Elliott MJ, Strobel S. Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL8: C3 is not essential. Cardiovasc Res 1995;30:676-681.
42. [42] Léculier C, Couprie N, Adeleine P, et al. The effects of high molecular weight- and low molecular weight-heparins on superoxide ion production and degranulation by human polymorphonuclear leukocytes. Thromb Res 1993;69:519-531.
43. [43] Mickelson JK, Simpson PJ, Lucchesi BR, et al. Streptokinase improves reperfusion blood flow after coronary artery occlusion. Int J Cardiol 1989;23:373-384.
44. [44] Higginson LAJ, Sheldrick KR, Temple SV, Beanlands DS. Intracoronary streptokinase: effects on reperfusion hemorrhage and regional myocardial blood flow in the anesthetized dog. J Cardiovasc Pharmacol 1987;9:509-514.
45. [45] Puckett SW, Digerness SB, Bowdon HR, Rogers WJ, Rackley CE. Direct effects of streptokinase on the isolated rat myocardium. J Cardiovasc Pharmacol 1984;6:1120-1123.
46. [46] Smith EF III, Nichols AJ, Selers TS, et al. Reduction in myocardial ischemic/reperfusion injury and neutrophil accumulation after therapeutic administration of streptokinase. J Cardiovasc Pharmacol 1991;18:729-738.
47. [47] Frangi D, Gardinali M, Conciato L, et al. Abrupt complement activation and transient neutropenia in patients with acute myocardial infarction treated with streptokinase. Circulation 1994;89:76-80.
48. [48] Hansen PR, Kharazmi A. Effect of streptokinase on human neutrophil function in vitro and in patients with acute myocardial infarction. J Mol Cell Cardiol 1994;26:1061-1068.